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Colchicine attenuates inflammatory cell infiltration and extracellu-
lar matrix accumulation in diabetic nephropathy. Am J Physiol
Renal Physiol 297: F200 –F209, 2009. First published April 15,
2009; doi:10.1152/ajprenal.90649.2008.—Recent studies have dem-
onstrated that an inflammatory mechanism contributes to the patho-
genesis of diabetic nephropathy (DN). It is also known that colchicine
(Col) can prevent various renal injuries via its anti-inflammatory
action. However, the effect of colchicine on DN has never been
explored. This study was undertaken to elucidate the effect of colchi-
cine on inflammation and extracellular matrix accumulation in DN. In
vivo, 64 rats were injected with diluent (C; n  32) or streptozotocin
intraperitoneally (DM, n  32). Sixteen rats from each group were
treated with Col. In vitro, rat mesangial cells and NRK-52E cells were
cultured in media with 5.6 mM glucose (NG) or 30 mM glucose (HG)
with or without 108 M Col. Monocyte chemotactic protein-1
(MCP-1) mRNA expression was determined by real-time PCR (RT-
PCR), and the levels of MCP-1 in renal tissue and culture media were
measured by ELISA. RT-PCR and Western blotting were also per-
formed for intercellular adhesion molecule-1 (ICAM-1) and fibronec-
tin (FN) mRNA and protein expression, respectively, and immuno-
histochemical staining (IHC) for ICAM-1, FN, and ED-1 with renal
tissue. Twenty-four-hour urinary albumin excretion at 6 wk and 3 mo
were significantly higher in DM compared with C rats (P 0.05), and
colchicine treatment significantly reduced albuminuria in DM rats
(P  0.05). Col significantly inhibited the increase in MCP-1 mRNA
expression and protein levels under diabetic conditions both in vivo
and in vitro. ICAM-1 and FN expression showed a similar pattern to
the expression of MCP-1. IHC revealed that the number of ED-1()
cells were significantly higher in DM compared with C kidney (P 
0.005), and this increase was significantly attenuated by Col treatment
(P  0.01). In conclusion, Col prevents not only inflammatory cell
infiltration via inhibition of enhanced MCP-1 and ICAM-1 expression
but also ECM accumulation in DN. These findings provide a new
perspective on the renoprotective effects of Col in DN.
inflammation; MCP-1; ICAM-1; fibronectin; afferent arteriole; con-
traction; losartan
INFILTRATION OF INFLAMMATORY cells in renal tubulointerstitium is
commonly seen in both human diabetic patients and experimental
diabetic animals (4, 12, 46). Monocytes/macrophages are the
principle inflammatory cells found in the diabetic kidney, and
recent studies have suggested that monocytes/macrophages play
an important role in the pathogenesis of glomerulopathy and
tubulointerstitial lesions in diabetic nephropathy. The administra-
tion of anti-inflammatory agents, such as mycophenolate mofetil
(MMF) (43) and retinoic acid (16), and the use of irradiation (40)
reduced inflammatory cell infiltration and prevented renal injury
in experimental diabetic animals. These findings suggest that an
inflammatory mechanism may also contribute to the pathogenesis
of diabetic nephropathy.
Monocytes/macrophages are extravasculated from the blood-
stream and attracted to the target tissue through a process
mediated by various chemokines and adhesion molecules such
as monocyte chemotactic protein (MCP)-1 and intercellular
adhesion molecule (ICAM)-1. In the kidney, MCP-1 is ex-
pressed in mesangial cells and tubular epithelial cells (34, 39)
and is known to be involved in the pathogenesis of various
renal diseases, including diabetic nephropathy. Previous stud-
ies have demonstrated that plasma MCP-1 levels are increased
in type 1 diabetes with microalbuminuria (3) and that urinary
levels of MCP-1 are also increased in accordance with the
extent of albuminuria (1, 28). Renal expression of ICAM-1, a
cell surface glycoprotein that plays a major role in the regula-
tion of interactions with immune cells and whose expression is
upregulated at the sites of inflammation, is also known to be
increased in experimental type 1 and type 2 diabetic animals
(8, 42). These findings suggest that MCP-1 and ICAM-1 may
play an important role in the pathogenesis of diabetic nephrop-
athy via inducing inflammatory cell infiltration.
Colchicine is an “old” drug commonly used to relieve pain
in acute gout and is known to inhibit the function and motility
of granulocytes and other motile cells by binding to microtu-
bular protein, which leads to the depolarization and disappear-
ance of the fibrillary microtubular structures (17). In addition,
colchicine has been used to prevent amyloidosis secondary to
familial Mediterranean fever (31) and has been demonstrated
to prevent experimental pulmonary and hepatic fibrosis by
suppressing the release of fibronectin and stimulating tissue
collagenase activity (21, 26, 36, 38). Furthermore, recent
studies have shown that colchicine prevents renal injury in an
animal model of chronic cyclosporine nephrotoxicity via its
antiapoptotic and anti-inflammatory action (11, 24, 25). To our
knowledge, however, there has not been a study that analyzed
the effect of colchicine in diabetic nephropathy. In this study,
we investigated the effect of colchicine on the expression of
MCP-1, ICAM-1, and fibronectin in experimental diabetic
kidney and in high glucose-stimulated mesangial cells and
tubular epithelial cells. In addition, the relationship between
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the extent of inflammatory cell infiltration and fibronectin
expression in renal tissue was elucidated.
MATERIALS AND METHODS
Animals
All animal studies were conducted under an approved protocol.
Rats weighing 250–280 g were injected with either diluent [n  32,
control (C)] or 65 mg/kg streptozotocin (STZ) intraperitoneally [n 
32, diabetes (DM)]. Diabetes was confirmed by tail-vein blood glu-
cose levels on day 3 postinjection. After confirmation of diabetes, 16
rats from each group were treated with 30 g kg1 day1 of colchi-
cine intraperitoneally (CCol, DMCol). Rats were housed in a
temperature-controlled room and were given free access to water and
standard laboratory chow during the study period. Eight rats from
each group were killed after 6 wk and the remainders after 3 mo.
Body weights were checked biweekly, and kidney weights were
measured at the time of death. Serum glucose, alanine aminotransfer-
ase (ALT), aspartate aminotransferase (AST), blood urea nitrogen
(BUN), and creatinine levels, and 24-h urinary albumin were also
measured at the time of death. Blood glucose was measured with a
glucometer and 24-h urinary albumin excretion by ELISA (Nephrat II,
Exocell, Philadelphia, PA). Serum ALT, AST, BUN, and creatinine
levels were determined by an automatic biochemical analyzer.
Cell Culture
Primary culture of mesangial cells was done as previously de-
scribed (18). Identification of mesangial cells was performed by their
characteristic stellate appearance in culture and confirmed by immu-
nofluorescent microscopy for the presence of actin, myosin, and
Thy-1 antigen and the absence of factor VIII and cytokeratin (Synbi-
otics, San Diego, CA). Mesangial cells and NRK-52E cells, immor-
talized rat tubular epithelial cells, were maintained in RPMI 1640 and
DMEM medium, respectively, supplemented with 5% FBS, 100 U/ml
penicillin, 100 mg/ml streptomycin, and 26 mM NaHCO3, and were
grown at 37°C in humidified 5% CO2 in air. Subconfluent mesangial
cells and NRK-52E cells were serum restricted for 24 h, after which
the medium was replaced by serum-free medium containing 5.6 mM
glucose (NG), NG24.4 mM mannitol (NGM), or 30 mM glucose
(HG) with or without 108 M colchicine (Col). At 24 h after the
media change, cells were harvested and the conditioned culture media
were collected.
Methylthiazoletetrazolium Assay
To examine the cytotoxicity of colchicine, mesangial cells and
NRK-52E cells were cultured in 96-well culture plates, phenol red-
free DMEM with 1 mg/ml of methylthiazoletetrazolium (MTT) was
added to each well after the experimental periods and incubated for
2 h at 37°C in humidified 5% CO2 in air. Extraction buffer (20% SDS,
50% N,N-dimethylformamide, pH 4.7) was added to the wells, which
were further incubated overnight at 37°C. Optical density (OD) was
measured with a microplate reader (SpectraMax 340, Molecular
Devices, Sunnyvale, CA) at a wavelength of 562 nm. The OD of the
NG cells was assigned a relative value of 100. The experiments were
performed in triplicate.
Measurement of MCP-1 by ELISA
A piece of snap-frozen renal tissue and phenol-free media were
used for the measurement of MCP-1. Renal tissue was pulverized with
a mortar and pestle while frozen, homogenized in 10 mM HEPES, pH
7.9, 10 mM KCl, 0.1 mM EGTA, 1 mM DTT, and a broad-spectrum
proteinase inhibitor cocktail (Boehringer Mannheim, Mannheim, Ger-
many). Both renal tissue homogenates and conditioned media were
centrifugation at 4,000 g for 20 min at 4°C, and the supernatants were
collected and stored at 80°C.
The levels of MCP-1 were determined using a commercial ELISA
kit (Biosource, Invitrogen, Carlsbad, CA) according to the manufac-
turer’s protocol. Briefly, 50 l of incubation buffer, 50 l of standard
diluent buffer, and 50 l of sample were dispensed into a 96-well
microplate coated with anti-rat MCP-1 antibody, and then 50 l of
biotinylated anti-MCP-1 solution was added to each well and incu-
bated for 90 min at room temperature. After the wells were washed
four times, 100 l of streptavidin-horseradish peroxidase was added
and then incubated for 30 min at room temperature. After another four
washes, addition of 100 l of stabilized chromogen was followed by
30-min incubation at room temperature and in the dark. Finally, 100
l of stop solution was added and the OD was determined at 450 nm
using an ELISA microtiter plate reader. The kit for rat MCP-1 was
species specific and sensitive up to 750 pg/ml. All the concentrations
of MCP-1 were normalized to the total protein amount.
Total RNA Extraction
Total RNA from renal cortical tissue was extracted as previously
described (18). Briefly, 100 l of RNA STAT-60 reagent (Tel-Test,
Friendswood, TX) was added to the renal cortical tissues, which were
lysed by freezing and thawing three times. Another 700 l of RNA
STAT-60 reagent was then added, and the mixture was vortexed and
stored for 5 min at room temperature. Next, 160 l of chloroform was
added and the mixture was shaken vigorously for 30 s. After 3 min,
the mixture was centrifuged at 12,000 g for 15 min at 4°C and the
upper aqueous phase containing the extracted RNA was transferred to
a new tube. RNA was precipitated from the aqueous phase by adding
400 l of isopropanol and then pelleted by centrifugation at 12,000 g
for 30 min at 4°C. The RNA precipitate was washed with 70%
ice-cold ethanol, dried using a Speed Vac, and dissolved in DEPC-
treated distilled water. RNA yield and quality were assessed based on
spectrophotometric measurements at wavelengths of 260 and 280 nm.
Table 1. Animal data
6-Wk 3-Mo
C (n  8) CCol (n  8) DM (n  8) DMCol (n  8) C (n  8) CCol (n  8) DM (n  8) DMCol (n  8)
Body weight g 4256 4185 2865* 2956* 6237 6119 3157* 3275*
Body wt/kidney wt, % 0.650.03 0.620.05 1.120.11* 0.850.08 0.550.04 0.530.06 1.250.13† 0.830.06‡
Glucose, mg/dl 1076 1105 48611† 47515† 1118 1108 47716† 46514†
BUN, mg/dl 19.31.1 21.31.5 24.42.3 22.91.7 20.51.0 21.11.3 25.32.1 22.61.9
Creatinine, mg/dl 0.810.03 0.750.05 0.890.10 0.850.08 0.790.04 0.820.05 0.880.11 0.860.09
ALT, U/l 553 596 634 585 564 575 604 645
AST, U/l 1159 11013 10911 11813 11110 1139 12111 11512
24-h Urine albumin, mg/day 0.330.04 0.370.07 1.180.15* 0.570.13‡ 0.380.06 0.350.07 2.890.20* 1.100.10‡
Values are means  SE. n  no. of rats; C, control; Col, colchicine; DM, diabetic; BUN, blood urea nitrogen; ALT, alanine aminotransferase; AST, aspartate
aminotransferase. *P  0.05 vs. C and CCol groups. †P  0.01 vs. C and CCol groups. ‡P  0.05 vs. DM group.
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Total RNA from mesangial cells and NRK-52E cells was extracted
similarly.
Reverse Transcription
First-strand cDNA was made by using a Boehringer Mannheim
cDNA synthesis kit (Boehringer Mannheim). Two micrograms of
total RNA extracted from renal cortex and cultured cells were reverse
transcribed using 10 M random hexanucleotide primer, 1 mM dNTP,
8 mM MgCl2, 30 mM KCl, 50 mM Tris HCl, pH 8.5, 0.2 mM
dithiothreithol, 25 U RNAse inhibitor, and 40 U AMV reverse
transcriptase. The mixture was incubated at 30°C for 10 min and 42°C
for 1 h, followed by inactivation of the enzyme at 99°C for 5 min.
Real-Time PCR
The primers used for MCP-1, ICAM-1, fibronectin, and 18s amplifi-
cation were as follows: MCP-1 sense 5-TCTCTTCCTCCACCACTAT-
GCA-3, antisense 5-GGCTGAGACAGCACGTGGAT-3; ICAM-1
sense 5-AGGTATCCATCCATCCCAC-3, antisense 5-GCCGAGGT-
TCTCGTCTTC-3; fibronectin sense 5-TGACAACTGCCGTAGAC-
CTGG-3, antisense 5-TAC TGGTTGTAGGTGTGGCCG-3; and 18s
sense 5-AGTCCCTGCCCTTTGT ACACA-3, antisense 5-GATC-
CGAGGGCCTCACTAAAC-3. cDNAs from 25 ng RNA of renal
cortical tissue or cultured cells per reaction tube were used for amplifi-
cation.
Using the ABI PRISM 7700 Sequence Detection System (Applied
Biosystems, Foster City, CA), PCR was performed with a total
volume of 20 l in each well, containing 10 l of SYBR Green PCR
Master Mix (Applied Biosystems), 5 l of cDNA, and 5 pM sense and
antisense primers. Primer concentrations were determined by prelim-
inary experiments that analyzed the optimal concentrations of each
primer. Each sample was run in triplicate in separate tubes to permit
quantification of the gene normalized to the 18s rRNA. The PCR
conditions were as follows: 35 cycles of denaturation at 94.5°C for
30 s, annealing at 60°C for 30 s, and extension at 72°C for 1 min.
Initial heating at 95°C for 9 min and final extension at 72°C for 7 min
were performed for all PCRs.
After real-time PCR, the temperature was increased from 60 to
95°C at a rate of 2°C/min to construct a melting curve. In addition,
standard curves of threshold cycle values against the log values of a
10-fold serial dilution of cDNA were constructed and the amplifica-
tion efficiencies were calculated for all target genes. The slopes of the
standard curve for MCP-1, ICAM-1, fibronectin, and 18s were3.36,
3.39, 3.45, and 3.28, respectively, and there was no significant
difference in PCR efficiencies among the four genes. A control
without cDNA was run in parallel with each assay. The cDNA content
of each specimen was determined using a comparative CT method
with 2CT. The results are given as relative expression of MCP-1,
ICAM-1, and fibronectin normalized to the expression of the 18s
housekeeping gene.
Western Blot Analysis
Renal cortical tissue and cultured cells harvested from plates were
lysed in SDS sample buffer [2% SDS, 10 mM Tris HCl, pH 6.8, 10%
(vol/vol) glycerol], treated with Laemmli sample buffer, heated at
100°C for 5 min, and electrophoresed in an 8% acrylamide denaturing
SDS-polyacrylamide gel. Proteins were then transferred to a Hybond-
ECL membrane using a Hoeffer semidry blotting apparatus (Hoeffer
Instruments, San Francisco, CA), and the membrane was then incu-
bated in blocking buffer A (1	 PBS, 0.1% Tween 20, and 8% nonfat
milk) for 1 h at room temperature, followed by an overnight incuba-
tion at 4°C in a 1:1,000 dilution of polyclonal antibodies to rat
ICAM-1 (R&D systems, Minneapolis, MN), fibronectin (Santa Cruz
Biotechnology, Santa Cruz, CA), or 
-actin (Sigma, St. Louis, MO).
The membrane was then washed once for 15 min and twice for 5 min
in 1	 PBS with 0.1% Tween 20. Next, the membrane was incubated
in buffer A containing a 1:1,000 dilution of horseradish peroxidase-
linked donkey anti-goat IgG (Amersham Life Science, Arlington
Heights, IL). The washes were repeated, and the membrane was
developed with a chemiluminescent agent (ECL; Amersham Life
Science). The band densities were measured using TINA image
software (Raytest, Straubenhardt, Germany).
Immunohistochemical Staining
For immunohistochemical staining, slices of kidney were snap-
frozen in optimal cutting temperature (OCT) solution and 4-m
sections of tissues were utilized. Slides were fixed in acetone for 10
min, air dried for 10 min at room temperature, and blocked with 10%
donkey serum for 20 min at room temperature. For ICAM-1, fibronec-
tin, and ED-1 staining, the primary polyclonal antibody to ICAM-1,
the extracellular domain of fibronectin, or ED-1 (Chemicon Interna-
tional, Billerica, MA), respectively, was diluted 1:100 with 2% casein
in BSA and applied for overnight incubation at room temperature.
After washing, a secondary donkey anti-goat antibody was added for
20 min and the slides were then washed and incubated with a tertiary
PAP complex for 20 min. DAB was added for 2 min, and the slides
were counterstained with hematoxylin. To determine the semiquanti-
tative score for ICAM-1 and fibronectin staining within the glomeruli
and tubulointerstitial area, photographs of at least 20 glomeruli under
Fig. 1. Renal MCP-1, ICAM-1, and fibronectin mRNA/18s rRNA ratios in
6-wk control (C), Ccolchicine (Col), diabetic (DM), and DMCol rats.
There were 1.7- and 1.9-fold increases in renal MCP-1/18s rRNA and ICAM-
1/18s rRNA ratios, respectively, in DM compared with C rats, and these
increases in MCP-1 and ICAM-1 mRNA expression were significantly abro-
gated by colchicine treatment. In contrast, there was no significant difference
in the fibronectin mRNA/18s rRNA ratio among the 4 groups. *P  0.05 vs.
other groups.
Fig. 2. Renal MCP-1 mRNA/18s rRNA ratios and
MCP-1 levels in 3-mo C, CCol, DM, and
DMCol rats. There were 3.1- and 2.2-fold in-
creases in the renal MCP-1/18s rRNA ratio and
MCP-1 protein levels, respectively, in DM com-
pared with C rats, and these increases in MCP-1
expression were significantly inhibited by the ad-
ministration of colchicine. *P  0.01 vs. C and
CCol. #P  0.05 vs. DM. †P  0.05 vs. other
groups.
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	400 magnification and 20 tubulointerstitial fields under 	200 mag-
nification, respectively, were taken. Afterward, the positive-staining
intensity of 1 to 4 compared with a negative control (score  0),
in which the immunohistochemical staining was performed without
the primary antibodies, were defined by one investigator in a blinded
fashion, based on the lightness and darkness of the brownish color
using a digital image analyzer (MetaMorph version 4.6r5, Universal
Imaging, Downingtown, PA). The staining score was obtained by
multiplying the intensity of staining by the percentage of glomeruli
or tubulointerstitium staining for that intensity; these numbers
were then added for each experimental animal to give the staining
score [ (intensity of staining) 	 (% of glomeruli or tubuloin-
terstitium with that intensity)]. The number of ED-1-positive cells
was counted in at least 20 glomeruli and 20 fields of the tubuloin-
terstitium/section under 	400 magnification.
Determination of Podocyte Numbers
Immunohistochemical staining for WT-1 was also performed to
determine the number of podocytes as previously described (2).
Briefly, two adjacent semithin sections 3 m apart were observed in
pairs at a magnification of 	400, and the nuclei present in the top
section but not in the bottom section were counted and summed. Ten
glomeruli in 5 rats from each group and 13–15 semithin sections from
the midglomerular area were examined.
Statistical Analysis
All values are expressed as means  SE. Statistical analysis was
performed using the statistical package SPSS for Windows Ver. 11.0
(SPSS, Chicago, IL). Results were analyzed using the Kruskal-Wallis
nonparametric test for multiple comparisons. Significant differences
by the Kruskal-Wallis test were further confirmed by the Mann-
Whitney U-test. The correlation between fibronectin mRNA expres-
sion and the number of ED-1-positive cells within the glomeruli and
tubulointerstitium was determined by Pearson’s correlation analysis.
P values 0.05 were considered to be statistically significant.
RESULTS
Animal Studies
Animal data. All animals gained weight over the experimen-
tal period, but body weight was highest in C rats. The ratios of
kidney weight to body weight in DM rats at 6 wk and 3 mo
were significantly higher than those in C and CCol rats, and
the increase in the ratio of kidney weight to body weight in
3-mo DM rats was significantly abrogated by the administra-
tion of colchicine (P  0.05). The mean blood glucose levels
in DM and DMCol rats were significantly higher compared
with C and CCol rats throughout the study period (P 0.01).
Compared with the C and CCol groups, 24-h urinary albumin
excretion at 6 wk and 3 mo was significantly higher in DM rats,
and colchicine treatment significantly reduced albuminuria in
DM rats (P  0.05). The serum levels of BUN and creatinine
were slightly higher in DM rats compared with the other
groups but did not reach statistical significance. On the other
hand, there was no difference in ALT and AST levels among
the four groups (Table 1).
In the preliminary experiments using diabetic rats treated
with 2 U/day of insulin (Ultralente, Eli Lilly, Indianapolis, IN),
the increase in MCP-1, ICAM-1, and fibronectin expression in
3-mo diabetic kidneys was significantly ameliorated by insulin
treatment, suggesting that these changes in STZ-induced dia-
betic rats were not due to STZ per se. The results of this study,
Fig. 3. Renal ICAM-1 and fibronectin mRNA/18s
rRNA ratios in 3-mo C, CCol, DM, and
DMCol rats. There were 2.3- and 3.7-fold in-
creases in ICAM-1 and fibronectin mRNA/18s
rRNA ratios, respectively, in DM relative to C
rats, and these increases in ICAM-1 and fibronec-
tin mRNA expression were significantly amelio-
rated with colchicine treatment. *P  0.05 vs.
other groups. #P  0.01 vs. other groups.
Fig. 4. Representative Western blot of ICAM-1
and fibronectin in 3-mo C, CCol, DM, and
DMCol rats (representative of four blots). Re-
nal ICAM-1 and fibronectin protein expression
were significantly increased in DM compared
with C rats, and these increases were significantly
attenuated by the administration of colchicine. In
contrast, there was no difference in 
-actin pro-
tein expression among the four groups. *P 0.01
vs. C and CCol. #P  0.05 vs. DM.
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therefore, included only the data for C, CCol, DM, and
DMCol rats.
Effect of colchicine on renal cortical MCP-1, ICAM-1, and
fibronectin mRNA expression at 6 wk. Renal MCP-1 and
ICAM-1 mRNA expression assessed by real-time PCR was
significantly increased in DM compared with C rats (P 
0.05), and these increases were significantly abrogated by the
administration of colchicine (P 0.05). The MCP-1/18s rRNA
and ICAM-1/18s rRNA ratios were 1.7- and 1.9-fold higher in
DM compared with C rats, respectively, and colchicine treat-
ment ameliorated these increases by 76.9 and 69.0%, respec-
tively. In contrast, there was no significant difference in fi-
bronectin mRNA expression among the four groups (Fig. 1).
Effect of colchicine on renal cortical MCP-1 mRNA expres-
sion and protein levels at 3 mo. Renal MCP-1 mRNA expres-
sion was significantly increased in 3-mo DM compared with C
rats (P  0.01), and this increase in MCP-1 mRNA expression
was significantly inhibited by the administration of colchicine
(P  0.05). The MCP-1 mRNA/18s rRNA ratio was 3.1-fold
higher in 3-mo DM compared with C rats, and colchicine
treatment attenuated this increase by 67.9% (Fig. 2). The levels
of renal MCP-1 assessed by ELISA were also significantly
Fig. 5. Immunohistochemical staining (IHC)
for ICAM-1, fibronectin, and ED-1 (as a
marker of macrophages) in 3-mo C, CCol,
DM, and DMCol rats. Glomerular (A) and
tubulointerstitial (B) ICAM-1 and fibronectin
staining were significantly increased in DM
relative to C rats, and these increases were
significantly abrogated by colchicine treat-
ment. In addition, there were significantly
more ED-1-positive cells (arrowhead) in DM
compared with C rats, and colchicine signifi-
cantly reduced the number of glomerular and
tubulointerstitial macrophages in DM rats.
C: IHC scores for ICAM-1 and fibronectin
within the glomeruli and the tubulointerstitial
area were significantly higher in DM rats rel-
ative to C rats, and colchicine treatment sig-
nificantly inhibited these increases in DM rats
(	400). *P  0.05 vs. other groups. #P 
0.01 vs. C and CCol. †P  0.05 vs. DM.
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higher in 3-mo DM relative to C rats (598.4 49.3 vs. 268.3
18.5 ng/g, P  0.05), and the increase in MCP-1 levels in
DM rats was significantly ameliorated by colchicine treatment
(357.3  25.3 ng/g, P  0.05) (Fig. 2).
Effect of colchicine on renal cortical ICAM-1 and fibronec-
tin mRNA expression at 3 mo. As seen in Fig. 3, ICAM-1
mRNA/18s rRNA ratio was significantly higher in 3-mo DM
compared with C rats (P  0.05), and colchicine treatment
significantly attenuated this increase in renal ICAM-1 mRNA
expression in DM rats (P  0.05). To elucidate the effect of
colchicine on ECM accumulation in experimental diabetic
nephropathy, fibronectin expression was determined with renal
cortical tissue. The renal fibronectin mRNA/18s rRNA ratio
was significantly higher in 3-mo DM relative to C rats (P 
0.01), and this increase was significantly inhibited with colchi-
cine treatment (P  0.01) (Fig. 3).
Effect of colchicine on renal cortical ICAM-1 and fibronec-
tin protein expression at 3 mo. Renal ICAM-1 and fibronectin
protein expression assessed by Western blotting was also
significantly increased in 3-mo DM compared with C rats (P
0.01), and colchicine treatment significantly abrogated these
increases in DM rats (P  0.05) (Fig. 4). In addition, immu-
nohistochemical staining for ICAM-1 and fibronectin con-
firmed the real-time PCR and Western blot findings. There
were significant increases in glomerular and tubulointerstitial
ICAM-1 and fibronectin staining in the 3-mo DM relative to
the C group, and these increases in DM rats were significantly
ameliorated by the administration of colchicine (Fig. 5).
Effect of colchicine on macrophage accumulation in diabetic
nephropathy at 3 mo. The number of glomerular and tubulo-
interstitial macrophages (mainly located in the interstitium)
assessed by immunohistochemical staining with ED-1 anti-
body was significantly higher in 3-mo DM compared with C
rats (22.2  4.2 vs. 3.4  0.4, P  0.005), and colchicine
treatment significantly decreased the number of ED-1-positive
cells in DM rats (9.6  1.0) (P  0.01) (Fig. 5).
Correlation between fibronectin mRNA expression and the
number of ED-1-positive cells. A correlation analysis was
performed to elucidate the relationship between fibronectin
mRNA expression and macrophage infiltration within the glo-
meruli and tubulointerstitium (n  32). Fibronectin mRNA
expression was significantly correlated with the number of
infiltrated ED-1-positive cells in the kidney (r  0.81, P 
0.001) (Fig. 6).
Podocyte numbers at 3 mo. Compared with C (168.3  8.2)
and CCol rats (171.1  6.7), the number of podocytes was
significantly decreased in DM rats (139.9  6.5), and the
reduction in podocyte numbers was inhibited in DM rats
treated with colchicine (162.1  5.5) (P  0.05).
Cell Culture Studies
Effect of colchicine on cell viability. The concentrations of
colchicine (108 M) used in this study did not affect cell
viability, which was assessed by an MTT assay (97.3  8.2%
vs. NG).
Effect of colchicine on MCP-1 mRNA expression and pro-
tein levels. MCP-1 mRNA expression assessed by real-time
PCR was significantly increased in HG-stimulated mesangial
cells (P  0.01) and NRK-52E cells (P  0.05), and this
increase in MCP-1 mRNA expression was significantly inhib-
ited by colchicine treatment (P  0.05). Compared with NG
cells, the MCP-1 mRNA/18s rRNA ratios were 2.1- and
1.9-fold higher in mesangial cells and tubular epithelial cells
exposed to HG, respectively, and colchicine treatment abro-
gated these increases by 75.3 and 84.7%, respectively (Fig. 7).
The levels of MCP-1 protein in conditioned culture media
assessed by ELISA showed a similar pattern to the mRNA
expression (Fig. 7).
Effect of colchicine on ICAM-1 and fibronectin mRNA ex-
pression. High glucose significantly induced ICAM-1 and
fibronectin mRNA expression in mesangial cells and NRK-52E
cells. Compared with NG cells, the ICAM-1 mRNA/18s rRNA
ratios were 2.2- and 2.1-fold higher in HG-stimulated mesan-
gial cells and tubular epithelial cells (P  0.01), respectively,
and these increases were ameliorated by 85.4 and 80.2%,
respectively, with colchicine treatment (P 0.05) (Fig. 8). The
fibronectin mRNA/18s rRNA ratio was also significantly in-
creased in HG-stimulated mesangial cells (P  0.01) and
NRK-52E cells (P  0.05) relative to NG cells by 132.3 and
74.0%, respectively, and these increases were significantly
attenuated with colchicine treatment (P  0.05) (Fig. 8).
Effect of colchicine on ICAM-1 and fibronectin protein ex-
pression. ICAM-1 and fibronectin protein expression in cul-
tured mesangial cells and NRK-52E cells showed similar
patterns to their respective mRNA expression (Fig. 9).
DISCUSSION
Recent clinical and experimental studies have demonstrated
that colchicine prevents renal injury in various glomerular and
tubulointerstitial diseases (11, 24, 25, 27, 31, 32), but the
effects of colchicine on proteinuria and pathological changes
have never been explored in diabetic nephropathy. In this
study, we demonstrate for the first time that inflammatory cell
infiltration and fibronectin expression in diabetic glomeruli and
tubulointerstitium are ameliorated by the administration of
colchicine. In addition, the results of this study suggest that the
anti-inflammatory effect of colchicine in diabetic nephropathy
is partly mediated by inhibiting the increase in MCP-1 and
ICAM-1 expression under diabetic conditions.
Colchicine is an alkaloid drug that has been used for many
decades in acute gouty arthritis. Colchicine binds to tubulin
Fig. 6. Correlation between fibronectin mRNA expression and the number of
ED-1-positive cells. Fibronectin mRNA expression correlated significantly
with the number of infiltrated macrophages in the glomeruli and tubulointer-
stitium.
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molecules and inhibits their polymerization into microtubules,
resulting in disruption of the mitotic spindles (17). Due to this
basic property, colchicine is mainly considered to be an anti-
mitotic drug. However, accumulating evidence has shown that
colchicine has additional effects on leukocytes and fibroblasts
(9, 10, 15, 33, 37). Colchicine alters leukocyte functions such
as adhesion and cytokine production (10). However, it has been
suggested that the main anti-inflammatory effect of colchicine
is attributed to its effect on leukocyte chemotaxis, which is
known to occur even at a very low concentrations of colchicine
(33). In addition, colchicine inhibits the release of fibronectin
and collagen to the extracellular space, reduces collagen-
processing enzyme, stimulates tissue collagenase activity, and
inhibits the proliferation of fibroblasts (9, 10, 15). Based on
these anti-inflammatory and antifibrotic effects of colchicine, it
has been used effectively to treat various diseases such as
familial Mediterranean fever (13, 48), primary biliary cirrhosis
(19, 23), and Behcet’s syndrome (47).
The beneficial effects of colchicine have also been demon-
strated in several experimental kidney disease models. McClurkin
et al. (27) showed that colchicine treatment protected renal
function and reduced fibrosis in a rabbit model of severe
crescentic glomerulonephritis. They observed significantly
lower serum creatinine concentrations and less renal interstitial
fibrosis in colchicine-treated animals compared with the vehi-
cle-treated group. In that study, however, regression analysis
failed to identify the sites at which colchicine was acting.
Improvement of interstitial fibrosis by colchicine was also
Fig. 7. MCP-1 mRNA/18s rRNA ratios and
secreted MCP-1 protein levels in cultured
mesangial cells (A) and NRK-52E cells (B)
exposed to 5.6 mM glucose (NG), NG24.4
mM mannitol (NGM), NG108 M col-
chicine (NGCol), 30 mM glucose (HG), or
HG108 M colchicine (HGCol) me-
dium. Compared with NG cells, the MCP-1
mRNA/18s rRNA ratios were 2.1- and 1.9-
fold higher in mesangial cells and tubular
epithelial cells exposed to HG, respectively,
and colchicine treatment attenuated these in-
creases by 75.3 and 84.7%, respectively. The
levels of MCP-1 protein in conditioned cul-
ture media assessed by ELISA showed a
similar pattern to the mRNA expression.
*P  0.01 vs. NG, NGM, and NGCol.
#P  0.05 vs. HG. †P  0.05 vs. other
groups.
Fig. 8. ICAM-1 and fibronectin mRNA/18s rRNA
ratios in cultured mesangial cells (A) and NRK-52E
cells (B) exposed to 5.6 mM glucose (NG),
NG24.4 mM mannitol (NGM), NG108 M
colchicine (NGCol), 30 mM glucose (HG), or
HG108 M colchicine (HGCol) medium.
Compared with NG cells, the ICAM-1 mRNA/18s
rRNA ratios were 2.2- and 2.1-fold higher in HG-
stimulated mesangial cells and tubular epithelial
cells, respectively, and these increases were abro-
gated by 85.4 and 80.2%, respectively, with col-
chicine treatment. The fibronectin mRNA/18s
rRNA ratio was also significantly increased in
HG-stimulated mesangial cells and NRK-52E cells
relative to NG cells by 132.3 and 74.0%, respec-
tively, and these increases were significantly ame-
liorated with colchicine treatment. *P  0.01 vs.
other groups. #P  0.01 vs. NG, NGM, and
NGCol. †P  0.05 vs. HG. ‡P  0.05 vs. other
groups.
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demonstrated in an animal model of chronic cyclosporine
nephrotoxicity (11, 24, 25). A recent study demonstrated that
cyclosporine-induced histological changes and the increases in
transforming growth factor (TGF)-
 expression, apoptotic
cells, and serum malonyldialdehyde levels were inhibited by
the administration of colchicine (11), suggesting that the pro-
tective effects of colchicine for cyclosporine nephrotoxicity
were attributed to the reduction in TGF-
 overexpression,
apoptosis, and oxidative damage. In contrast to the uniform
antifibrotic effect of colchicine, the effect of colchicine on
inflammatory cell infiltration is not consistent. Some studies
demonstrated that there were no significant differences in
inflammatory cell infiltration between colchicine- and vehicle-
treated rats with chronic cyclosporine nephrotoxicity (41),
whereas one study showed that colchicine treatment signifi-
cantly decreased the number of ED-1-positive cells along with
the decreases in osteopontin mRNA and protein expression in
these rats (24). The reasons for these differences in the anti-
inflammatory effect of colchicine in cyclosporine nephrotox-
icity are not clear, but differences between species, duration
of the animal experiments, and kidney lesions observed to deter-
mine the number of infiltrated inflammatory cells may contribute
to these disparities. The results of our study reveal decreases in
glomerular and tubulointerstitial fibronectin accumulation and
inflammatory cells infiltration in colchicine-treated diabetic
rats, suggesting that the antifibrotic and anti-inflammatory
effects of colchicine may also be operative in diabetic nephrop-
athy.
Even though the diabetic milieu per se, hemodynamic
changes, and local growth factors are considered mediators in
the pathogenesis of diabetic nephropathy, recent studies sug-
gest that an inflammatory mechanism may also contribute to
the development of diabetic nephropathy and that MCP-1 and
ICAM-1 are considered the central molecules involved in
macrophage/monocyte influx in diabetic nephropathy (5–7, 30,
42). In this study, we observed that MCP-1 and ICAM-1
expression was increased in experimental diabetic nephropa-
thy, which was associated with inflammatory cell infiltration,
and in high glucose-stimulated mesangial cells and tubular
epithelial cells, and these increases under diabetic conditions
were attenuated by colchicine treatment. Taken together, the
anti-inflammatory effect of colchicine in diabetic nephropathy
can be partly attributed to the suppression of MCP-1 and
ICAM-1 expression in mesangial cells and tubular epithelial
Fig. 9. Representative Western blot of ICAM-1
and fibronectin in cultured mesangial cells
(A) and NRK-52E cells (B) (representative of
4 blots). Cellular ICAM-1 and fibronectin
protein expression were significantly in-
creased in HG-stimulated mesangial cells and
tubular epithelial cells compared with NG
cells, and these increases were significantly
attenuated by colchicine treatment. In con-
trast, there was no difference in 
-actin pro-
tein expression among the groups. *P  0.05
vs. other groups.
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cells by colchicine. Recently, several studies have demon-
strated that podocytes express MCP-1 and its expression is
enhanced by high glucose and advanced glycation end-prod-
ucts (14, 16), suggesting that podocytes are also involved in the
inflammatory process under diabetic conditions. In addition,
administration of MMF and cartilage oligmeric matrix protein-
angiopoietin-1 suppressed MCP-1 and prevented podocyte loss
and foot process effacement in type 1 and type 2 diabetic animals,
respectively (22, 49). Since 24-h urinary albumin excretion and
podocyte loss were abrogated in diabetic rats by the adminis-
tration of colchicine in this study, we surmise that colchicine
may improve podocyte changes in diabetic rats, but further
study will be needed to clarify the direct effect of colchicine on
podocytes under diabetic conditions.
Once recruited monocytes/macrophages are activated, they
release lysosomal enzymes, nitric oxide, reactive oxygen spe-
cies, platelet-derived growth factor (PDGF), tumor necrosis
factor-, interleukin (IL)-1, and TGF-
, and in turn promote
renal injury (29, 35, 46). PDGF stimulates fibroblast prolifer-
ation (20, 44), and IL-1 induces the expression of TGF-
, the
most well-known profibrotic cytokine, in fibroblasts (45). In
MCP-1- and ICAM-1-deficient diabetic mice, renal fibrosis
also was significantly reduced along with less inflammatory
cell infiltration (5–7, 30), suggesting that the inhibition of
inflammatory cell recruitment may lead to a reduction in
extracellular matrix accumulation. The results of the present
study also showed that the increase in fibronectin expression
came after the increases in MCP-1 and ICAM-1 expression.
Therefore, we argue that one of the interesting findings of this
study, the amelioration of glomerular and tubulointerstitial
ECM accumulation in colchicine-treated diabetic rats, is a
consequence of reduced infiltration of inflammatory cells in
addition to the aforementioned antifibrotic effect of colchicine.
In summary, colchicine ameliorates inflammatory cell infiltra-
tion in diabetic nephropathy by inhibiting MCP-1 and ICAM-1
expression. In addition, enhanced fibronectin expression in the
diabetic kidney is attenuated by colchicine treatment. These
findings suggest that colchicine could be a useful drug for
preventing nephropathy in diabetes.
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